Form 4: Pharvaris CEO Berndt Modig Executes Planned Stock Sale

Pharvaris CEO Berndt Modig sold 2,291 shares of common stock on June 15, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• CEO Berndt Modig sold a total of 2,291 shares of Pharvaris N.V. common stock.
• The transactions occurred on June 15, 2026, at weighted average prices ranging from $31.0484 to $31.46 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares at predetermined times to avoid concerns regarding non-public information.
• Following these transactions, Mr. Modig retains direct ownership of 135,209 shares and indirect ownership of 950,000 shares through Schoodic Management BV.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, indicating the transaction was automated and not based on immediate market sentiment or non-public information.

Negatives

• Insider selling, even when planned, reduces the executive's direct equity stake in the company.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity may be perceived by some investors as a lack of long-term confidence, though this is standard executive practice.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The sales were executed pursuant to a Rule 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine practice in the biotechnology sector, allowing executives to diversify holdings without triggering market volatility or regulatory scrutiny.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives in publicly traded biotech firms to manage personal equity holdings.

Related Party Transactions

• The filing notes indirect ownership of 950,000 shares held by Schoodic Management BV, an entity controlled by the reporting person.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed through a pre-planned, automated mechanism.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Berndt Modig, Biotech, Equity